SCHEMBL16137286

SCHEMBL16137286

COc1cc(OC)c(F)c(C)c1C

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.42
CYP3A4 P08684 3/20 0.39
TUBB1 Q9H4B7 3/20 0.36
ALDH1A1 P00352 3/20 0.36
MAPT P10636 2/20 0.36
CA9 Q16790 1/20 0.36
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
CYP1A1 P04798 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP1B1 Q16678 1/20 0.33
KDM4E B2RXH2 1/20 0.33
TSHR P16473 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
PTGS2 P35354 1/20 0.33
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16071608 0.90 ACHE (0.40) ACHECYP3A4TUBB1ALDH1A1MAPT
SCHEMBL19732265 0.83 TUBB1 (0.43) ACHECYP3A4TUBB1ALDH1A1MAPT
SCHEMBL16071623 0.81 ACHE (0.52) ACHECYP3A4ALDH1A1MAPTCA9
SCHEMBL16071615 0.79 MAPT (0.36) ACHECYP3A4TUBB1ALDH1A1MAPT
SCHEMBL16071633 0.79 GAA (0.38) ACHECYP3A4TUBB1ALDH1A1MAPT
SCHEMBL19569162 0.79 CYP3A4 (0.36) ACHECYP3A4TUBB1ALDH1A1MAPT
SCHEMBL27988498 0.79 ACHE (0.46) ACHECYP3A4TUBB1ALDH1A1MAPT
SCHEMBL167017 0.78 TUBB1 (0.41) ACHECYP3A4TUBB1ALDH1A1MAPT
SCHEMBL25952537 0.76 ACHE (0.55) ACHECYP3A4TUBB1ALDH1A1MAPT
SCHEMBL684130 0.74 ACHE (0.59) ACHECYP3A4TUBB1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017192961-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION (US) 2017-11-09 WO disclosed
US-20160221966-A1 HETEROARYL COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2016-08-04 US disclosed
US-9321786-B2 Heteroaryl compounds and uses thereof CELGENE AVILOMICS RESEARCH, INC. (US) 2016-04-26 US disclosed
US-20140296233-A1 HETEROARYL COMPOUNDS AND USES THEREOF SANOFI (FR) 2014-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296233-A1 HETEROARYL COMPOUNDS AND USES THEREOF ABCG2, CYP3A43, CYP3A5 ACHE 210/4885CYP3A4 6/4885TUBB1 1807/4885
US-20160221966-A1 HETEROARYL COMPOUNDS AND USES THEREOF ABCG2, CYP3A43, CYP3A5 ACHE 210/4885CYP3A4 6/4885TUBB1 1807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.